<DOC>
	<DOCNO>NCT02150291</DOCNO>
	<brief_summary>Since success combination therapy PEG-IFN RBV contingent maintain adequate dos drug throughout treatment period , emergence hematological side effect expect require intervention . The hematological adverse effect lead trade-off continue treatment optimal dosage , clear virus , exacerbate thereby side effect versus decrease dosage relieve severe anemia , reduce thereby chance achieve sustained virological response ( SVR ) . Therefore , aim give Folic acid® Neurobion® HCV-infected patient treatment different type PEG-IFN plus ribavirin attempt evaluate efficacy safety prophylactic treatment prevent hematological adverse effect . Preventing adverse effect without interfere therapeutic efficacy different type PEG-IFN plus ribavirin HCV patient lead good health outcome improvement quality life ( HRQOL ) .</brief_summary>
	<brief_title>A Pilot Study Assess Efficacy Safety Folic Acid and/or Vitamin B Complex Hepatitis C Infected Patients Treated With Pegylated Interferon Ribavirin .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Chronic hepatitis C patient sex eligible inclusion HCV RNA positive , naive PEGINF RBV , abnormal serum alanine transaminase level two occasion precede six month . Patients significant hematological abnormality baseline , neutropenia ( ANC &lt; 1200 x 103 cells/µL ) , thrombocytopenia ( &lt; 70 x 103 cells/ µL ) , anemia ( &lt; 10.5 g/dL ) , exclude . Patients also exclude study participation serum creatinine ≥1.70 mg/dL ( 150 µmol ) , hepatitis B surface antigen positivity , decompensated cirrhosis , form liver disease attributable HCV . Patients severe depression psychosis , uncontrolled seizure , poorly control cardiovascular disease , diabetes mellitus , autoimmune disorder also ineligible . Women ineligible study participation pregnant unwilling use least 2 form effective contraception entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>